Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234988 | 0.91 | LMNA (0.36) | LMNATSHRALDH1A1MAPTKDM4E | |
| SCHEMBL6928053 | 0.91 | LMNA (0.36) | LMNATSHRALDH1A1MAPTKDM4E | |
| SCHEMBL10087479 | 0.82 | TSHR (0.33) | TSHR | |
| SCHEMBL8155173 | 0.80 | TSHR (0.33) | LMNATSHRALDH1A1MAPTKDM4E | |
| SCHEMBL29980213 | 0.79 | MGAM (0.38) | TSHRALDH1A1 | |
| SCHEMBL711473 | 0.78 | CYP2D6 (0.42) | — | |
| SCHEMBL29133363 | 0.78 | ALDH1A1 (0.39) | LMNATSHRALDH1A1MAPTKDM4E | |
| SCHEMBL1260190 | 0.78 | CYP2D6 (0.42) | — | |
| SCHEMBL4909003 | 0.78 | CYP2D6 (0.42) | — | |
| SCHEMBL6400340 | 0.77 | ALDH1A1 (0.35) | LMNAALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124790-B2 | Preparation process useful in synthesis of atorvastatin | MEDICHEM KOREA CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| US-8124790-B2 | Preparation process useful in synthesis of atorvastatin | MEDICHEM KOREA CO., LTD. (KR) | 2012-02-28 | — | — | US | disclosed |
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA CO., LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | MEDICHEM KOREA CO., LTD. (KR) | 2011-05-12 | — | — | US | disclosed |
| US-6962994-B2 | Process for the synthesis of 1,3-diols | WARNER-LAMBERT COMPANY, LLC (US) | 2005-11-08 | — | — | US | disclosed |
| US-20040006231-A1 | Process for the synthesis of 1,3-diols | BOSCH ROBERT LEE (US) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112309-A1 | PREPARATION PROCESS USEFUL IN SYNTHESIS OF ATORVASTATIN | HMGCR, DHCR7, LIPA | LMNA 1146/4885TSHR 3029/4885ALDH1A1 3842/4885 |
| US-20040006231-A1 | Process for the synthesis of 1,3-diols | HSD17B7, HSD11B1, BCKDK | LMNA 2782/4885TSHR 2963/4885ALDH1A1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.